GLP-1 Safety and Sourcing: Approved Products vs Compounded vs Fake

The FDA has approved several GLP-1 receptor agonist drugs for the treatment of type 2 diabetes and, in some cases, chronic weight management. Semaglutide is marketed as Ozempic (injectable, for type 2 diabetes), Wegovy (injectable, for chronic weight management), and Rybelsus (oral, for type 2 diabetes), all manufactured by Novo Nordisk. Tirzepatide, a dual GIP/GLP-1 receptor agonist, is marketed as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management) by Eli Lilly.

Earlier GLP-1 drugs include liraglutide (Victoza for diabetes, Saxenda for weight management), exenatide (Byetta, Bydureon), dulaglutide (Trulicity), and lixisenatide (Adlyxin). Each of these has completed the full FDA approval process, including extensive clinical trials demonstrating safety and efficacy for their approved indications.

FDA-approved GLP-1 products are manufactured under strict Good Manufacturing Practice (GMP) standards, with every batch tested for purity, potency, sterility, and stability. They come with FDA-approved labeling that details proper dosing, titration schedules, known side effects, contraindications, and drug interactions. These products represent the gold standard for GLP-1 therapy and should be the first-line option whenever available and accessible.

The unprecedented demand for semaglutide and tirzepatide, combined with supply shortages, created a large market for compounded GLP-1 products. During periods when these drugs were on the FDA Drug Shortage List, licensed compounding pharmacies (both 503A and 503B) were permitted to compound versions of these medications. This led to a proliferation of telehealth platforms and compounding pharmacies offering GLP-1 preparations, often at significantly lower prices than the brand-name products.

Compounded GLP-1 products differ from their FDA-approved counterparts in important ways. They are not FDA-approved, which means they have not undergone the same level of testing for safety, efficacy, and quality. The active ingredient may be a different salt form (such as semaglutide sodium rather than semaglutide base), the formulation may differ, and the manufacturing processes are not subject to the same GMP requirements as commercial manufacturers (though 503B facilities must meet cGMP standards).

The regulatory status of compounded GLP-1 products is dynamic and depends on whether the FDA-approved versions remain on the drug shortage list. When a shortage ends, the legal basis for compounding copies of the commercially available product narrows significantly. Patients using compounded GLP-1 products should stay informed about shortage status changes and discuss transition plans with their healthcare providers. Our compounding explainer covers this framework in detail.

The FDA has issued numerous warning letters and taken enforcement actions against companies selling unapproved GLP-1 products. These actions have targeted online retailers selling products labeled as semaglutide or tirzepatide without FDA approval, compounding pharmacies operating outside the legal framework, and companies making unsubstantiated therapeutic claims about their products.

Common violations cited in FDA warning letters include marketing unapproved new drugs, manufacturing drugs without proper registration and inspections, making false or misleading claims about product safety and efficacy, and selling products that are adulterated or misbranded. The FDA has also taken action against companies selling products that contain undisclosed active ingredients or that do not contain the labeled amount of the stated active ingredient.

Patients can search the FDA's warning letters database to check whether a specific company or pharmacy has received enforcement action. A warning letter does not necessarily mean the company has ceased operations, but it does indicate that the FDA has identified significant regulatory violations. Companies that receive warning letters are expected to take corrective action, and failure to do so can result in injunctions, seizures, or criminal prosecution.

Counterfeit and mislabeled GLP-1 products pose serious health risks. The FDA and other regulatory agencies have identified counterfeit versions of Ozempic and other GLP-1 products in the US supply chain. These products may contain no active ingredient, the wrong active ingredient, incorrect dosages, or harmful contaminants. Some counterfeit products have been found with insulin instead of semaglutide, which could cause dangerous hypoglycemia.

Red flags that suggest a product may be counterfeit or illegitimate include: unusually low prices compared to the brand-name product; purchase from an unverified or unlicensed source; packaging that looks different from the manufacturer's official packaging (wrong fonts, colors, lot numbers, or expiration dates); products that do not require a prescription; products shipped from overseas without proper import documentation; and products with labels in a language other than English if sold in the US market.

For injectable GLP-1 products, examine the pen device or vial carefully. Authentic products from Novo Nordisk and Eli Lilly have specific security features, including unique lot numbers and serialization that can be verified. If you suspect you have received a counterfeit product, do not use it. Report it to the FDA's MedWatch program and contact your healthcare provider for guidance on obtaining a verified replacement.

Patients seeking GLP-1 therapy should follow a systematic approach to ensure they are receiving safe, legitimate products. The following checklist provides a framework for evaluating any GLP-1 product or provider.

• Start with your physician. A licensed healthcare provider should evaluate whether GLP-1 therapy is appropriate for your medical situation, prescribe the correct medication and dose, and monitor your response to treatment.
• Use a licensed pharmacy. Verify the pharmacy's state license through the state board of pharmacy or NABP. If the pharmacy claims to be a 503B outsourcing facility, confirm its FDA registration.
• Confirm the product source. For FDA-approved products, verify that the product comes from an authorized distributor. For compounded products, confirm the compounding pharmacy's credentials and the prescriber's involvement.
• Check for a valid prescription requirement. Any legitimate source of GLP-1 drugs will require a valid prescription from a licensed prescriber. If a seller offers GLP-1 products without a prescription, it is operating outside the legal framework.
• Verify current shortage status. If you are considering a compounded GLP-1 product, check whether the FDA-approved version is currently on the FDA Drug Shortage List. This affects the legality of the compounded product.
• Report suspicious products. If you receive a product that appears counterfeit, mislabeled, or causes unexpected adverse effects, report it to the FDA's MedWatch program and your state board of pharmacy.